Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.
Eleven pediatric patients, aged 1 to 10 years and with symptomatic human immunodeficiency virus infection, were treated with 6 or 10 mg of oral ribavirin per kg of body weight daily for 60 days. Safety and pharmacokinetic parameters were monitored; five children had comprehensive pharmacokinetic eva...
Guardat en:
| Publicat a: | Antimicrob Agents Chemother |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society for Microbiology (ASM)
1993
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC187703/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8460922/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.37.3.532 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|